| Literature DB >> 28834216 |
Stefano Bonelli1,2, Xenia Geeraerts1,2, Evangelia Bolli1,2, Jiri Keirsse1,2, Mate Kiss1,2, Ana Rita Pombo Antunes1,2, Helena Van Damme1,2, Karen De Vlaminck1,2, Kiavash Movahedi1,2, Damya Laoui1,2, Geert Raes1,2, Jo A Van Ginderachter1,2.
Abstract
Tumor-associated macrophages (TAM) are by now established as important regulators of tumor progression by impacting on tumor immunity, angiogenesis, and metastasis. Hence, a multitude of approaches are currently pursued to intervene with TAM's protumor activities, the most advanced of which being a blockade of macrophage-colony stimulating factor (M-CSF)/M-CSF receptor (M-CSFR) signaling. M-CSFR signaling largely impacts on the differentiation of macrophages, including TAM, and hence strongly influences the numbers of these cells in tumors. However, a repolarization of TAM toward a more antitumor phenotype may be more elegant and may yield stronger effects on tumor growth. In this respect, several aspects of TAM behavior could be altered, such as their intratumoral localization, metabolism and regulatory pathways. Intervention strategies could include the use of small molecules but also new generations of biologicals which may complement the current success of immune checkpoint blockers. This review highlights current work on the search for new therapeutic targets in TAM.Entities:
Keywords: M-CSF receptor; biologicals; immunotherapy; metabolism; small molecule inhibitors; tumor microenvironment; tumor-associated macrophages
Mesh:
Substances:
Year: 2017 PMID: 28834216 DOI: 10.1111/febs.14202
Source DB: PubMed Journal: FEBS J ISSN: 1742-464X Impact factor: 5.542